혈우병 치료 시장 규모, 점유율, 성장 분석 : 유형별, 약물 종류별, 치료법별, 환자별, 치료별, 투여 경로별, 최종 용도별, 지역별 - 산업 예측(2025-2032년)
Hemophilia Treatment Market Size, Share, Growth Analysis, By Type, By Drug Class, By Therapy, By Patient, By Treatment, By Route of Administration, By End-use, By Region - Industry Forecast 2025-2032
상품코드:1630625
리서치사:SkyQuest
발행일:2025년 01월
페이지 정보:영문 157 Pages
라이선스 & 가격 (부가세 별도)
한글목차
혈우병 치료 세계 시장 규모는 2023년 134억 달러로 평가되며, 2024년 142억 8,000만 달러에서 2032년 238억 2,000만 달러로 성장할 것으로 예상되며, 예측 기간(2025-2032년) 동안 연평균 6.6%의 CAGR로 성장할 것으로 예상됩니다.
세계 혈우병 치료 시장은 의료기술의 발전, 질병에 대한 인식의 증가, 의료 서비스 접근성 향상 등으로 인해 크게 성장하고 있습니다. 이 시장에는 혈우병 A와 B 치료에 필수적인 유전자재조합 혈액응고 제8인자 및 혈액응고 제9인자 제제 등 다양한 제품들이 제공되고 있습니다. 이러한 농축 제제는 결핍된 응고인자를 보충함으로써 출혈 위험을 크게 감소시킵니다. 또한, 유전자 치료는 혈우병의 핵심적인 유전적 결함을 교정하는 획기적인 치료법의 잠재력을 가지고 있습니다. 주요 성장 요인으로는 혈우병 유병률 증가, 의료비 지출 증가, 맞춤형 의료로의 전환 등을 들 수 있습니다. 유전공학과 생명공학의 지속적인 발전으로 시장은 혈우병의 치료 성적을 개선하고 결정적인 치료법을 찾기 위한 혁신적인 치료 솔루션을 준비할 준비가 되어 있습니다.
목차
소개
조사 목적
조사 범위
정의
조사 방법
정보 조달
2차 데이터와 1차 데이터 방법
시장 규모 예측
시장 가정과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porters 분석
주요 시장 인사이트
핵심성공요인
경쟁 정도
주요 투자 기회
시장 생태계
시장 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
규제 상황
사례 연구
기술의 진보
혈우병 치료 시장 규모 : 유형별
시장 개요
혈우병 A
혈우병 B
혈우병 치료 시장 규모 : 약물 종류별
시장 개요
바소프레신
응고인자
혈우병 치료 시장 규모 : 치료법별
시장 개요
재조합 응고인자 농축 요법
혈장 유래 응고인자 농축물 요법
비인자 보충 요법
반감기 연장 제품
데스모프레신
항섬유소용해제
유전자 치료 제품
기타
혈우병 치료 시장 규모 : 환자별
시장 개요
소아
성인
혈우병 치료 시장 규모 : 치료별
시장 개요
예방
온디맨드
혈우병 치료 시장 규모 : 투여 경로별
시장 개요
주사
코 스프레이
경구
혈우병 치료 시장 규모 : 최종 용도별
시장 개요
병원
클리닉
혈우병 치료 센터
기타
혈우병 치료 시장 규모
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5개사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채용한 전략
시장의 최근 동향
기업의 시장 점유율 분석(2024년)
주요 기업 개요
기업 개요
제품 포트폴리오 분석
부문별 점유율 분석
매출 전년비 비교(2022-2024)
주요 기업 개요
Pfizer Inc.(United States)
Bayer AG(Germany)
Novo Nordisk A/S(Denmark)
CSL Behring(Australia)
BioMarin Pharmaceutical Inc.(United States)
Sangamo Therapeutics(United States)
Octapharma AG(Switzerland)
Roche Holding AG(Switzerland)
Sanofi S.A.(France)
Takeda Pharmaceutical Company Limited(Japan)
Grifols S.A.(Spain)
Alnylam Pharmaceuticals, Inc.(United States)
Biogen Inc.(United States)
Kedrion Biopharma(Italy)
SOBI(Sweden)
Genentech, Inc.(United States)
Shire plc(United Kingdom)
Aptevo Therapeutics(United States)
Catalyst Biosciences(United States)
uniQure N.V.(Netherlands)
결론과 추천사항
ksm
영문 목차
영문목차
Global Hemophilia Treatment Market size was valued at USD 13.4 billion in 2023 and is poised to grow from USD 14.28 billion in 2024 to USD 23.82 billion by 2032, growing at a CAGR of 6.6% during the forecast period (2025-2032).
The global Hemophilia Treatment Market has experienced remarkable expansion, driven by medical technology advancements, heightened awareness of the disorder, and improved healthcare access. The market offers a diverse range of products, including clotting factor concentrates like recombinant factor VIII and factor IX, essential for treating hemophilia A and B, respectively. These concentrates significantly decrease bleeding risks by replenishing absent clotting factors. Additionally, gene therapy represents a groundbreaking potential cure, aiming to rectify the genetic defects at the disorder's core. Key growth factors include the rising prevalence of hemophilia, increasing healthcare spending, and a shift towards personalized medicine. With the continuous evolution in genetic engineering and biotechnology, the market is poised for innovative treatment solutions to enhance outcomes and seek definitive cures for hemophilia.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemophilia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Hemophilia Treatment Market Segmental Analysis
Global Hemophilia Treatment Market is segmented by Type, Drug Class, Therapy, Patient, Treatment, Route of Administration, End-use and region. Based on Type, the market is segmented into Hemophilia A and Hemophilia B. Based on Drug Class, the market is segmented into Vasopressin and Coagulation factors. Based on Therapy, the market is segmented into Recombinant coagulation factor concentrates therapy, Plasma derived coagulation factor concentrates therapy, Non-factor replacement therapy, Extended half-life products, Desmopressin, Antifibrinolytic agents, Gene therapy products and Others. Based on Patient, the market is segmented into Pediatric and Adult. Based on Treatment, the market is segmented into Prophylaxis and On demand. Based on Route of Administration, the market is segmented into Injectable, Nasal spray and Oral. Based on End-use, the market is segmented into Hospitals, Clinics, Hemophilia treatment centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Hemophilia Treatment Market
The global Hemophilia Treatment market is primarily driven by continuous technological advancements in the realm of diagnostics and therapies. Leading players in the industry are focused on developing innovative, cutting-edge tools and medications designed to enhance the effectiveness and precision of hemophilia treatment. Furthermore, substantial investments aimed at expanding specialized hemophilia treatment centers (HTCs) worldwide contribute significantly to the positive market outlook. The combination of enhanced technology and the growth of dedicated treatment facilities is expected to propel the market forward, ensuring better patient outcomes and increased accessibility to quality care for individuals living with hemophilia.
Restraints in the Global Hemophilia Treatment Market
The Global Hemophilia Treatment market faces significant restraints due to the stringent regulatory approval processes enforced by health authorities. These rigorous requirements necessitate that manufacturers undergo comprehensive assessments of safety and efficacy, which can be both time-consuming and resource-heavy. As a result, the lengthy approval times can hinder the market entry of innovative treatment options, ultimately stalling growth and limiting patient access to new therapies. This regulatory burden can create barriers for companies seeking to introduce advancements in hemophilia care, thereby impacting the overall development and competitiveness of the market.
Market Trends of the Global Hemophilia Treatment Market
The global hemophilia treatment market is witnessing significant growth driven by an increase in the incidence of genetic disorders and a rising population of hemophiliac patients. Enhanced diagnostic capabilities and growing awareness around preventive treatment options are further propelling market expansion. Major pharmaceutical firms are realizing lucrative opportunities due to heightened diagnosis rates, while regulatory bodies are initiating campaigns to promote early diagnosis and testing for newborns. This awareness boost not only accelerates treatment accessibility but also invigorates research and development efforts, as companies seek innovative solutions amidst a limited therapeutic landscape. Overall, these trends signal a robust growth trajectory for the market.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement
Global Hemophilia Treatment Market Size by Type & CAGR (2025-2032)
Market Overview
Hemophilia A
Hemophilia B
Global Hemophilia Treatment Market Size by Drug Class & CAGR (2025-2032)
Market Overview
Vasopressin
Coagulation factors
Global Hemophilia Treatment Market Size by Therapy & CAGR (2025-2032)
